In November 2019 Diabetes New Zealand presented a petition with close to 28,000 signatures to parliament as a result of dissatisfaction and feedback from people with diabetes. 

Pharmac restrict their funding of Diabetes related devices and medications. In our petition we highlighted the need for Continuous Glucose Monitors that are essential for people with Type 1 diabetes and drew attention to the valuable new classes of medication available overseas for people with type 2 diabetes.

The petition asked: “That the House of Representatives urge Pharmac to fund Continuous Glucose Monitors (CGM), GLP1 agonists including Bydureon, Byetta, Lyxumia, and Victoza, SGLT2 inhibitors including Forxiga and Jardiance, and DPP-4 inhibitors including Januvia, Onglyza, and Trajenta”.

Submission

In January 2020 we subsequently made a written submission providing background information on the matters outlined in our petition. 

To view that submission click here

We have a template letter if you wish to write directly to your local MP here